Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
September 16, 2024 07:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the...
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
July 25, 2024 07:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the...
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
July 02, 2024 07:00 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has...
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
June 24, 2024 07:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has...
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
May 10, 2024 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
March 22, 2024 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced...
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
December 05, 2023 08:30 ET
|
Checkpoint Therapeutics, Inc
Upcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc....
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
November 13, 2023 17:00 ET
|
Checkpoint Therapeutics, Inc
Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 Recent publication of cosibelimab pivotal trial results in the Journal for ImmunoTherapy...
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer
October 18, 2023 08:30 ET
|
Checkpoint Therapeutics, Inc
Cosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous...
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
August 14, 2023 16:15 ET
|
Checkpoint Therapeutics, Inc
Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024 Longer-term cosibelimab results...